Neisseria meningitidis serogroup C capsular polysaccharide-specific B-cell receptor (MenC BCR) (MenC BCR)

Neisseria meningitidis serogroup C capsular polysaccharide-specific B-cell receptors (BCRs) are specialized surface immunoglobulins on B cells that recognize the unique α(2→9)-linked sialic acid capsule of serogroup C meningococci [1]. These receptors are fundamental to the development of protective immunity, as their engagement by vaccine antigens or natural infection triggers the activation and differentiation of B cells into memory cells and antibody-secreting plasma cells [2]. The antibodies produced are highly specific to the MenC polysaccharide and function by initiating the classical complement pathway, leading to the direct lysis of the bacteria or their clearance via opsonophagocytosis [3]. In the context of pharmacology, these BCRs are the primary immunological targets for conjugate vaccines, which link the polysaccharide to a carrier protein to recruit T-cell help and ensure long-lasting memory [4]. Monitoring the induction of these receptors and their secreted antibody products, typically through serum bactericidal assays, is the standard method for assessing vaccine efficacy against invasive meningococcal disease [5]. Understanding the repertoire and affinity maturation of these receptors is crucial for designing next-generation vaccines that provide broader and more durable protection [6].

Other names

MenC-specific B-cell receptorAnti-MenC antibodyNeisseria meningitidis serogroup C antibodyMenC capsular polysaccharide-specific immunoglobulin

Vaccine antigens bind to these receptors to stimulate B-cell activation, leading to the production of high-affinity antibodies that mediate bacterial killing through complement activation and opsonophagocytosis.